Global EditionASIA 中文双语Français
World
Home / World / Americas

Moderna to begin phase-3 COVID-19 vaccine trial in July

Xinhua | Updated: 2020-06-12 09:06
A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, US, May 18, 2020. [Photo/Agencies]

WASHINGTON - US biotech firm Moderna said on Thursday it expects to begin a phase-3 study of its COVID-19 vaccine candidate in July.

Moderna has finalized the phase-3 study protocol based on feedback from the US Food and Drug Administration. The randomized, 1:1 placebo-controlled trial is expected to include approximately 30,000 participants enrolled in the United States and is expected to be conducted in collaboration with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, according to a release of the company.

With the phase-3 dose being finalized at 100 mcg, Moderna remains on track to be able to deliver approximately 500 million doses per year, and possibly up to 1 billion doses per year beginning in 2021, said the release.

"We look forward to beginning our Phase 3 study of mRNA-1273 with some 30,000 participants in July," said Moderna Chief Medical Officer Tal Zaks.

"Moderna is committed to advancing the clinical development of mRNA-1273 as safely and quickly as possible to demonstrate our vaccine's ability to significantly reduce the risk of COVID-19 disease," he said.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US